---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Transplantation and investigational therapies"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Transplantation and investigational therapies. Topics: Investigational agents and modalities named in the 2025 guideline, Gene and cell-based therapies remain preclinical, Nizubaglustat phase 3 trial in late-infantile and juvenile forms, Efavirenz phase 2 trial in adult and late juvenile-onset disease, and 3 further topics. 7 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/transplantation-and-investigational-therapies"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Transplantation and investigational therapies

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Transplantation and Investigational Therapies

<a id="topic-2.2.2.1.6-1"></a>

### Investigational agents and modalities named in the 2025 guideline

> “Other experimental therapies include the orally administered agents efavirenz, a non‐nucleoside reverse transcriptase antiretroviral inhibitor, and nizubaglustat, a selective dual inhibitor of ceramide glucosyltransferase and non‐lysosomal neutral glucosylceramidase (NLGase)”
> “In addition, several other therapeutic modalities, including gene therapy, antisense oligonucleotide (ASO) therapy for patients with specific targetable mutations, and CRISPR/Cas9 technology in animal studies, are underway with positive preliminary findings”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.2.1.6-2"></a>

### Gene and cell-based therapies remain preclinical

> “Gene therapy and cell‐based therapies (mesenchymal stem cells) have gained much interest in the pre‐clinical setting,”
> “but there have been no clinical trials to our knowledge to date.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.2.1.6-3"></a>

### Nizubaglustat phase 3 trial in late-infantile and juvenile forms

> “An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis”

Source: [ClinicalTrials.gov NCT07054515](https://clinicaltrials.gov/study/NCT07054515)

<a id="topic-2.2.2.1.6-4"></a>

### Efavirenz phase 2 trial in adult and late juvenile-onset disease

> “This is a single-center, phase II clinical trial to evaluate the efficacy and safety of Efavirenz in addition to standard of care in patients diagnosed with adult or late juvenile-onset NPC with cognitive impairment.”
> “All enrolled patients will be treated orally with 25 mg/d of Efavirenz for 52 weeks (1 year).”

Source: [Gascón-Bayarri et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9726274/)

<a id="topic-2.2.2.1.6-5"></a>

### Systematic review assessment of evidence for investigational agents

> “Evidence for vorinostat, NAC, efavirenz, and nizubaglustat was limited by small samples and early-phase or uncontrolled designs.”

Source: [Nafees et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13702622/)

<a id="topic-2.2.2.1.6-6"></a>

### Allogeneic bone marrow transplantation in NPC2: case reports

> “In this report we describe the first successful allogeneic bone marrow transplantation for this condition in a 16-month-old boy homozygous for the NPC2 p.E20X mutation, which has hitherto been reported to cause disease with a severe phenotype.”
> “This 'graft versus substrate' reaction was managed with intensive immune suppressant therapy, and it gradually resolved as the substrate was cleared by the engrafted donor macrophages.”

Source: [Bonney et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20393800/)

> “In contrast to the previously reported patients with the same mutations, our patient has no respiratory compromise and has made some developmental progress (especially gross motor), though is significantly delayed (particularly in speech and language).”
> “Haematopoietic stem cell transplantation (HSCT) could be considered for patients with this mutation as long as performed early in the course of the disease.”

Source: [Breen et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23219289/)

<a id="topic-2.2.2.1.6-7"></a>

### Liver transplantation in children with neonatal liver failure: case series

> “Nine children were identified (six centres).”
> “Neonatal acute liver failure was the most common indication for LTx (seven children).”
> “Neurological symptoms developed in 4/7 (57%) patients at median 9 (range: 5–13) years following LTx.”
> “Neurological disease is not prevented in the majority of patients.”
> “LTx still remains controversial in NPC.”

Source: [Modin et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8470073/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
